12 unknown, 3 completed, 2 not yet recruiting, 1 recruiting. 14 Phase 3, 13 Phase 2, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Unknown 10, Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 13 | Unknown 10, Completed 2, Not yet recruiting 1 |
| Not applicable | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
Follow this condition Literature Review of Conditioning trials Research Report on Conditioning
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML MTBF regimen - Relapse Leukemia, Refractory Acute Myeloid Leukemia | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 37 | 2024-05-01 | 2024-04-26 |
| Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT MA-BUCY2, BUCY2 - Haploidentical Stem Cell Transplantation, Conditioning | Not applicable | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 264 | 2023-04-15 | 2023-04-18 |
| Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT modified BEAM, BEAM - Autologous Stem Cell Transplantation, Conditioning | Not applicable | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 122 | 2023-04-15 | 2023-04-18 |
| Novel Cardiac Pacing to Initiate Cardiac Remodeling in Heart Failure novel atrial pacing approach, sham pacing approach - Cardiomyopathies, Heart Rate | Not applicable | Completed | Denise Hodgson-Zingman | 5 | 2022-11-02 | 2023-05-16 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 232 | 2022-07-01 | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2022-07-01 | 2023-03-21 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2021-01-15 | 2021-01-19 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - TP53, Myeloid Tumors | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-10-01 | 2019-10-10 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-09-01 | 2019-09-23 |
| BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 20 | 2018-11-01 | 2018-11-07 |
| Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT Decitabine, Busulfan (BU), Fludarabine(Flu) - Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 60 | 2018-06-15 | 2020-12-22 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-01-02 | 2020-02-25 |
| Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT Decitabine plus Modified BUCY, Modified BUCY - Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 90 | 2017-09-01 | 2017-08-21 |
| BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2017-07-05 | 2017-10-12 |
| G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 202 | 2016-04-18 | 2022-02-14 |
| IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY) - Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 153 | 2016-01-01 | 2020-03-03 |
Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (3) · Cardiomyopathies (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (9) · Hematologic Diseases (8) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Leukemia (4) · Leukemia, Myeloid (4) · Bone Marrow Diseases (3) · Cardiovascular Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Blood Protein Disorders (1) · Disease Attributes (1) · Heart Diseases (1) · Hemorrhagic Disorders (1)
Busulfan (14) · Cyclophosphamide (11) · Decitabine (9) · fludarabine (6) · Etoposide (4) · Melphalan (3) · Cytarabine (2) · venetoclax (2) · Carmustine (1) · Influenza Vaccines (1) · Semustine (1) · Thiotepa (1)
Nanfang Hospital, Southern Medical University (12) · First Affiliated Hospital Xi'an Jiaotong University (3) · Denise Hodgson-Zingman (1) · First Affiliated Hospital of Zhejiang University (1) · The First Affiliated Hospital of Soochow University (1)
China (15) · United States (1)
Qifa Liu (10) · Xiaoning Wang, M.D. (2) · Denice Hodgson-Zingman, MD (1) · Depei Wu, MD (1) · Xiaoning Wang (1)